吡格列酮和非诺贝特在调节代谢综合征大鼠主动脉重构中的作用  

Effect of Fenofibrate and Pioglitazone on Regulation of Arteriae Aorta Remodeling in the Metabolic Syndromic Rats

作　　者：罗玉梅[1] 姜德谦[1] 万新红[2] 刘显庆[1] 柴湘平[1] 郭洪波[2] 陈朝霞[2] 

机构地区：[1]中南大学湘雅医学院湘雅二医院心内科,湖南省长沙市410011 [2]广东省深圳市龙岗区人民医院心内科,广东省深圳市518172

出　　处：《中国动脉硬化杂志》2009年第12期966-970,共5页Chinese Journal of Arteriosclerosis

基　　金：深圳市科技基金重点资助项目(200643)

摘　　要：目的探讨非诺贝特和吡格列酮对果糖饲养的代谢综合征大鼠主动脉重构的影响。方法用高果糖饮食饲养SD大鼠构建代谢综合征大鼠模型,分别单用非诺贝特或吡格列酮及二者合用干预。分析比较两种药物单用及合用干预后,代谢综合征大鼠在主动脉形态结构上的差异。结果非诺贝特和吡格列酮干预均可使代谢综合征大鼠主动脉内膜变平滑,抑制中膜平滑肌细胞增殖,使血管壁变薄;吡格列酮干预还使代谢综合征大鼠主动脉中膜平滑肌细胞及弹力纤维排列更为整齐。合用吡格列酮和非诺贝特干预,使主动脉结构更趋向于正常状态。结论非诺贝特和吡格列酮干预均可抑制代谢综合征大鼠主动脉的病理性重构;但单用非诺贝特作用不如单用吡格列酮明显;合用非诺贝特和吡格列酮,可通过不同的机制和作用靶点,产生协同作用,进一步改善及逆转代谢综合征状态下的血管重构,降低发生心血管疾病的危险性。Aim To explore the effect of fenofibrate（Fen） and pioglitazone（Pio） on arteriae aorta remodeling in the fructose-induced metabolic syndromic（MS） Rats.Methods SD rats breeded with high fructose fed to raise MS rats,and Fen or Pio were used to intervent MS rats singly and jointly.The differences in arteriae aorta morphosis of MS rats were analyzed and compared among groups with different intervents.Results The arteriae aorta remodeling were amended in MS rats intervened by Fen and Pio.Relative to MS rats,rats intervened with Fen or Pio singly exhibited a more smoothing aortic tunica intima,less vascular medio-smooth muscle proliferation,and thinner vascular wall.Pio-intervention even displayed a more regular array of medio-smooth muscle cell and elastic fibers.Combination with fenofibrate and pioglitazone intervented MS rats,which built a more normal arteriae aorta in morphosis.Conclusions Intervention with fenofibrate or pioglitazone singly can restrain arteriae aorta pathologic remodeling in MS rats.The effectiveness of pioglitazone is more significant than that of fenofibrate.Synergistic effect of fenofibrate and pioglitazone can further improve and even reverse the vascular remodeling in MS rats by different mechanisms and acting targets.

关 键 词：代谢综合征 大鼠模型 血管重构 过氧化体增殖物激活型受体α/γ 

分 类 号：R541[医药卫生—心血管疾病]